Just have a look BTA with a Mcap of around $220 Million
Around $85 Million in the bank
GSK is producing now around 60 Million courses of Relenza per year
GSK gets about $20 per course so earnings of $1.2 Billion
Biota gets 7% royalty on Relenza payements which means they will get around $84 Million per year.
And this is all without Lani and all the other products they have in the pipeline.
Biota has become a Cash cow and could become easy a target for a predator who is eyeing all that cash.
And I have not even mentioned that I do believe that GSK will increase production again as we now all know that Relenza is the only Antiviral left standing.
The capping of the share price could be from a big boy who has been trying to get hold of as much shares as possible but lucky not many holders like to part with them.
Good luck to all and I have loaded up the truck with Biota shares waiting the story to unfold.
please do your own research
jojo
BTA Price at posting:
$1.31 Sentiment: LT Buy Disclosure: Held
